Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

Graves’ orbitopathy (GO) is the most common extrathyroidal manifestation of Graves’ disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label multicenter study of glucocorticoid-resistant GO treated with TCZ. The...

Full description

Bibliographic Details
Main Authors: Lara Sánchez-Bilbao, David Martínez-López, Marcelino Revenga, Ángel López-Vázquez, Elia Valls-Pascual, Belén Atienza-Mateo, Beatriz Valls-Espinosa, Olga Maiz-Alonso, Ana Blanco, Ignacio Torre-Salaberri, Verónica Rodríguez-Méndez, Ángel García-Aparicio, Raúl Veroz-González, Vega Jovaní, Diana Peiteado, Margarita Sánchez-Orgaz, Eva Tomero, Francisco J. Toyos-Sáenz de Miera, Valvanera Pinillos, Elena Aurrecoechea, Ángel Mora, Arantxa Conesa, Manuel Fernández-Prada, Juan A. Troyano, Vanesa Calvo-Río, Rosalía Demetrio-Pablo, Íñigo González-Mazón, José L. Hernández, Santos Castañeda, Miguel Á. González-Gay, Ricardo Blanco
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Subjects:
Graves’ disease
extrathyroidal manifestations
thyroid-associated ophthalmopathy
Graves’ ophthalmopathy
corticoid-resistant
Tocilizumab
Online Access:https://www.mdpi.com/2077-0383/9/9/2816

Internet

https://www.mdpi.com/2077-0383/9/9/2816

Similar Items